Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tepha Inc.
Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
According to "European Markets for Heart Valve Repair and Replacement Products," Medtech Insight's recent report, in the coming years growth in the heart valve industry will be somewhat flat in Europe-with a compound annual growth rate in the overall number of procedures of 1.6% between now and 2013. However, that number reflects a drop in the number of mechanical valves used, and a rise in tissue valves, which are enjoying increased uptake with each generation of technological improvements.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
- Implantable Devices
- Surgical Equipment & Devices